Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Douglas Pharmaceuticals Limited

Latest From Douglas Pharmaceuticals Limited

US FDA Asks Manufacturers To Fix Disruption In Isotretinoin REMS

The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.

Risk Management Drug Safety

Pfizer sells Icagen drug discovery, not compounds

Four years after Pfizer acquired Icagen for $56m, the big pharma sold the drug discovery firm to XRpro Sciences for up to $11m, which would seem to be a big discount if the deal gave the buyer access to compounds generated by Icagen's ion channel biology platform.

Neurology Respiratory

FDA guides on abuse-deterrent opioids; generics direction pending

The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.


INTERVIEW: Actavis CEO Saunders staying put as Allergan deal nears close

Actavis CEO Brent Saunders has been the head of three different companies in less than two years, but with the $66bn acquisition of Allergan about to close any day now, he told Scrip that he's found the place where he plans to retire.

See All

Company Information

  • Industry
  • Biotechnology